VistaGen Therapeutics, Inc.
VTGN
VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing various medicines with the potential to care for anxiety, depression, and other disorders of the central nervous system (CNS). The company's CNS pipeline includes PH94B, a rapid-onset neuroactive nasal spray, which is in Phase III development for the acute treatment of anxiety in adulā¦ read more
Healthcare
Biotechnology
14 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$0.78
Price+5.11%
$0.04
1Y
Price
Market Cap
$25.491m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financials Overview
Key metrics over the past few years-7454.3%
EBITDA Margin-7526.0%
Net Profit Margin-5356.2%
Free Cash Flow MarginRevenue
$721k
+48.4%
1y CAGR+187.6%
3y CAGR+110.6%
5y CAGREarnings
-$62.236m
-21.0%
1y CAGR-15.2%
3y CAGR-17.4%
5y CAGREPS
-$1.91
-14.4%
1y CAGR+19.3%
3y CAGR+10.7%
5y CAGRBook Value
$66.339m
$80.929m
Assets$14.590m
Liabilities$1.865m
DebtDebt to Assets
2.3%
-
Debt to EBITDAFree Cash Flow
-$53.095m
-25.6%
1y CAGR-13.6%
3y CAGR-12.7%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company